Board

  • Mark G Lotter/ CEO and Co-Founder

    BSc. Pharm,MBA.

    Mark is an industry veteran having spent the last 20 years with a number of leading MNC’s and locals layers in both China and abroad.

    Mark has spent the last 14 years in China first building the commercial operations for AZ followed by setting a venture backed pharmaceutical company – NovaMed. NovaMed was sold to a US listed company SCLN in 2011 with Mark staying on until late 2012 to lead the China operations.

    Mark has recently established a new venture backed company – Nuance Biotech, led by a globally experienced team with a strong track in China and abroad. The company is focussed on targeting development , regulatory and commercial stage assets.

  • Dr. Eric Yu/ Matrix|Partners

    Eric was responsible for healthcare investment at Fidelity Growth Partners China from 2012 to 2014. From 2009 to 2012, Eric was the Deputy General Manager at the Northeastern Office of Shenzhen Capital Group. Before that Eric worked at UBS Investment Bank's Global Healthcare group and McKinsey's New York Office.
    Eric also worked as a researcher on bioinformatics and structure-based drug design at Yale and Columbia University, respectively.

  • Neo Zhang/ C-Bridge Capital

    Neo led the fund’s investments into a series of leading Chinese biotech companies including Ascletis, Innovent, I-Mab and Everest Medicines
    He has more than 12 years of experience in investment banking and private equity industry with a focus on China, spanning from BEI Capital, Capital Group, Morgan Stanley and BOC International
    He got his B.S. degree with honors from Hong Kong University, major in Mathematics.
  • Matthew Chang/ C-Bridge Capital

    Matthew has held a number of senior financing and consulting positions – these include : Managing Director KKR , Senior Global Partner Roland Berger , AlixPartners , Managing Director and Associated Director McKinsey.

  • Dr. Tong Zhang/ C-Bridge Capital

    Tong has held a variety of potions  : VP, head of Corporate BD at Wuxi AppTec , head of Business Development for MSD China , pan-regional lead for Emerging Market business development team at Merck & Co. and head of Business Development at EKR Therapeutics. Tong also had investment experience as a Director at ESP Equity Partners and equity analyst covering the US pharmaceutical industry for Credit Suisse.
    Tong received his Ph.D. in Biology from Columbia University and a B.S. degree in Biology from Wuhan University in China. He also performed post-doctoral research at Sloan-Kettering Cancer Center in New York in the lab of Nobel Laureate Dr. James Rothman.
Adverse reaction feedback:drugsafety@nuancepharma.cn Copyright 2017-2019 NUANCE BIOTECH INC reserved. 沪ICP备17029781号-4
Address: Room 2106 Ciro's Plaza, 388 Nanjing Rd.(W) Shanghai China, 200003 Email: info@nuancepharma.cn Tel: 021-32035318
  • 首页
  • 电话
  • 留言